Hemab Therapeutics Holdings, Inc. Common Stock COAG · SEC Filings

website

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming t...

Price42.81

Market Cap2 B

Float20.31 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 21, 2026

News

TYPE

HEADLINE

FILED AT

Prospectus

TYPE

HEADLINE

FILED AT

424B4

IPO | Offering amount: $301,500,000 | Shares: 16,750,000 | Price: $18.000 | Bank: Goldman Sachs & Co. LLC

May 1, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 1, 2026

S-1MEF

OFFERING

Apr 30, 2026

S-1/A

OFFERING - IPO | Bank: Goldman Sachs & Co. LLC; Jefferies; Evercore ISI; Wedbush PacGrow

Apr 30, 2026

S-1/A

OFFERING - IPO

Apr 28, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Apr 27, 2026

S-1/A

OFFERING - IPO | Bank: Goldman Sachs & Co. LLC; Jefferies; Evercore ISI; Wedbush PacGrow

Apr 27, 2026

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 6, 2026

Walbert Keli (Reporting)

Sep 25, 2026

Walbert Keli (Reporting)

Sep 25, 2026

SCHEDULE 13G

Novo Holdings A/S (Filed by)

Aug 14, 2026

SCHEDULE 13G

Avoro Capital Advisors LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G

Capital International Investors (Filed by)

Aug 12, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 1, 2026